Regardless of the cause of a disease, most diseases involve gene dysregulation. Omega Therapeutics is developing a new class of programmable, epigenomic, mRNA medicines designed to make specific epigenetic changes and correct abnormal gene expression to treat or cure diseases. We spoke to Mahesh Karande, president and CEO of Omega Therapeutics, about its pipeline of mRNA therapies, how they work, and its recently announced collaboration with Novo Nordisk to develop an epigenomic controller to treat obesity.
Cala Health Hopes to Win Over Payers and Providers with Its Bioelectric Medicine
Shaping the Emerging Bioeconomy
A Belief that Early Interventions Will Be the Key to Treating Alzheimer’s Disease
Transforming the Study of Microbes with High-Throughput Technology
Using RNA Diagnostics to Predict Patient Response to Immunotherapies
How a Clever Business Model May Accelerate the Use of Companion Diagnostics
Building Cell Therapies with Switches to Modulate Their Activity
Using Synthetic Biology to Build Intelligence into Cell and Gene Therapies
A Therapeutic Approach Built on Protein Degradation
Harnessing AI to Improve Sales and Marketing Decision-Making
A Doctor’s Quest to Cure His Own Rare Disease
Athersys Advances Off-the-Shelf Stem Cell Therapy for Stroke
Enlisting the Innate Immune System to Fight Cancer and other Diseases
Using AI to Improve Clinical Development
Addressing the Challenge of Making Antibody-Drug Conjugates
Targeting Regulators of Genes to Treat Cancer
Harnessing the Immune System to Diagnose and Treat Cancer
Using Synthetic Biology to Produce Cannabinoids
EpicentRx Hopes Rocket-Fuel-Derived Drug Will Propel It
Using Fruit Flies to Personalize Cancer Therapies
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Stuff To Blow Your Mind
Unexplainable
Ground Truths